Search
bimatoprost (Lumigan, Latisse)
Indications:
1) glaucoma, increased intraocular pressure
2) hypotrichosis, enhancement of eyelash growth [3]
Dosage:
- 1 drop QHS
Lumigan: 0.01% or 0.03%
Pharmacokinetics:
- no significant systemic accumulation [4]
- 1/2life 45 minutes
- peak plasma time < 10 minutes
- onset of action: 4hr (IOP reduction)
- peak effect: 8-12hours
- protein binding: 88%
- volume of distribution: 0.67 L/kg
- metabolism: oxidation; N-deethylation & glucuronidation
- excretion: urine (67%); feces (25%)
Adverse effects:
- common > 10%) [4]
- conjunctival hyperemia (25-45%)
- growth of eyelashes (15-45%)
- ocular pruritus (15-45%)
- uncommon 1-10%
- xerophthalmia (3-10%)
- visual disturbance (3-10%)
- ocular burning (3-10%)
- eye foreign body sensation (3-10%)
- eye pain (3-10%)
- pigmentation of the periocular skin (3-10%)
- blepharitis (3-10%)
- cataract (3-10%)
- superficial punctate keratitis (3-10%)
- eyelid erythema (3-10%)
- ocular irritation (3-10%)
- eyelash darkening (3-10%)
- ocular discharge (1-3%)
- tearing (1-3%)
- photophobia (1-3%)
- allergic conjunctivitis (1-3%)
- asthenopia (1-3%)
- increases in iris pigmentation (1-3%)
- conjunctival edema (1-3%)
- other
- blurred vision
- may permanently darken iris, eyelashes & eyelids
Mechanism of action:
1) prostaglandin analog
2) increases ouflow of aqueous humor
Notes: Manufacturer: Allergan
General
prostaglandin analog; prostanoid
Database Correlations
PUBCHEM correlations
References
- Prescriber's Letter 8(5):28 2001
- Prescriber's Letter 16(2): 2009
New Drugs Approved by the FDA in 2008
Detail-Document#: 250213
(subscription needed) http://www.prescribersletter.com
- Deprecated Reference
- Medscape: bimatoprost (Rx)
https://reference.medscape.com/drug/latisse-lumigan-bimatoprost-343605